ALZAN cohort
-
alpha-synuclein co-pathology, alpha-synuclein SAA, ALZAN cohort, Alzheimer’s disease, Brain, CSF biomarkers, lewy body dementia, memory clinic biomarkers, Neurodegenerative Diseases, neuroscience, RT-QuICAlpha-Synuclein SAA Detected 95% of Lewy Body Dementia in ALZAN
A 2026 ALZAN memory-clinic cohort found that cerebrospinal-fluid alpha-synuclein seed amplification assay…
